Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027 Initial clinical data for BDC-4182 Phase 1 dose escalation study now expected in 3Q 2026Company is implementing a 50% workforce reduction to extend cash runway into 2027 REDWOOD CITY, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced an update on the ongoing Phase 1 dose escalation study of BDC-4182, a next-generation Boltbody™ ISAC clinical candidate targeti...
Key Findings:US hotel RevPAR growth averaged -1% Y/Y QTD through August, decelerating ~60bps from 2Q. RevPAR growth has been slightly negative the last three months after flat growth in May and April. Through the first two weeks of September, US hotel RevPAR has continued to stabilize.International
Report Overview: Our analysis includes total web visits (desktop and mobile) to U.S. and international web domains, mobile app monthly active users (MAUs), daily active users (DAUs), and total time spent (where applicable). Throughout the report, we display Y/Y changes across each of these key metr
"Building Airbnb's Next Chapter":Brian Chesky, Co-Founder and CEO at AirbnbAirbnb CEO and Co-Founder Brian Chesky addressed Airbnb's lower-than-industry growth rate and shared his plan to reinvigorate growth to the teens-to-twenty percent range. The plan is centered around leveraging AI across the
A director at Delta Air Lines Inc sold 10,000 shares at 61.307USD and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
Key Findings:US hotel RevPAR growth averaged -1.4% Y/Y in July, decelerating ~100bps from 2Q. RevPAR growth has been slightly negative the last two months after flat growth in May and April. Through the first three weeks of August, US hotel RevPAR growth has stabilized, averaging -1% Y/Y.Internatio
Report Overview: Our analysis includes total web visits (desktop and mobile) to U.S. and international web domains, mobile app monthly active users (MAUs), daily active users (DAUs), and total time spent (where applicable). Throughout the report, we display Y/Y changes across each of these key metr
Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Next-generation claudin 18.2 ISAC BDC-4182 now in Phase 1 dose-escalation study Cash balance of $48.5 million as of June 30, 2025 anticipated to fund key milestones through mid-2026 REDWOOD CITY, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. “In the...
Following 2Q results, momentum seems most favorable for the companies below:META (Outperform) - While sentiment was already elevated ahead of the print, 2Q results were strong and guidance for 3Q was encouraging, with expectations for revenue growth ahead of initial St. estimates by ~700bps. Additi
Figure 1. 2Q25 ResultsSource: Company reports, Wedbush estimates, FactSet consensusAirbnb reported strong 2Q results and provided an in-line outlook for 3Q. Nights and Experiences booked growth in 2Q of +7.4% Y/Y was ~80bps above Street estimates. Revenue and adj. EBITDA were ahead of estimates by
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.